Compare Raymond James Financial, Inc. (RJF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs TG Therapeutics Inc — how do they compare? Raymond James Financial, Inc. trades at $158.28 (market cap $30.51B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Raymond James Financial, Inc. is far larger — about 3.7× TG Therapeutics Inc's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and TG Therapeutics Inc for 16 Days on average.
| RJF | TGTX | |
|---|---|---|
Market Cap | $30.51B | $8.16B |
Volume | 1,206,253 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $181.18 | $59.06 |
52-Week Low | $140.89 | $26.94 |
Typical Hold Time | 75 Days | 16 Days |
Enterprise Value | $24.37B | $8.37B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RJF trades at $158.28, up 0.63% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 exceeding expectations. Revenue grew to $13.84B in 2025, and net income margin stands at 15.37%. Recent news highlights executive leadership changes and a declared dividend of $0.54 per share payable in October 2026.
The outlook is mixed: analyst consensus is a 'Hold' with a $184 price target, implying potential upside, but technical indicators signal near-term caution. Key risks include rising expenses and market volatility, while growth drivers include wealth management expansion and investment banking recovery. The stock presents a balanced opportunity with solid fundamentals offset by technical headwinds.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
